Eyedaptic offering is now closed and is no longer accepting investments.

INVEST IN EYEDAPTIC TODAY!

Augmented Reality Glasses for Vision Loss

Eyedaptic glasses use augmented reality technology to improve vision for those who suffer from AMD (age-related macular degeneration) and other central vision impairments.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Eyedaptic

$665,255.45 Raised

REASONS TO INVEST

Reasons Icon

~400 million people worldwide suffer from various retinal diseases and nearly half of them suffer from AMD (Age-Related Macular Degeneration)

Reasons Icon

The only self-contained Augmented Reality glasses on the market, with over 40 degrees FOV (Field-of-View), to simulate natural vision!

Reasons Icon

Eyedaptic has 2 patents granted, 3 trademarks and 12 patents pending for their award winning AR visual aid

*All images are of past prototypes or our production product. Final results may differ.

Overview


Enhancing vision to revitalize life

Eyedaptic CEO, Jay Cormier, founded the company after his grandmother started losing her vision due to the incurable condition, AMD (age-related macular degeneration). Upon further research, he discovered that AMD is the leading cause of vision loss for people over 60, and affects more than 15 million Americans and 170 million people worldwide (source).


Furthermore, there are 400 million people suffering from retinal disease worldwide with 114 million people affected by Diabetic Related Retina Disease (DME & DR) and 98 million who have macular puckering/ scarring. Others suffer from retinal diseases like Stargardt’s Disease and Macular Pucker that also lead to a loss of central vision. (source, source, source)

Having had experience with Augmented Reality in the past, Cormier began to consider whether the technology could provide a solution to AMD. Cormier and his partner/CTO, Dave Watola, did not have medical backgrounds and so they sought the help of two ophthalmologists/retina specialists, Dr. Mitul Mehta and Dr. Brian Kim.


It quickly became clear to all of them that there was a significant need for a solution to AMD. So Cormier and Watola teamed up with the two doctors to found Eyedaptic.

*All images are of past prototypes or our production product. Final results may differ.

The Problem


No cure for the leading cause of age-related blindness

AMD is the leading cause of blindness for people over the age of 60. The disorder affects patients’ central vision, the fine, detailed segment of our vision that is used for reading or using a computer. This makes everyday tasks for sufferers extremely challenging, especially when many of us dependent on our phones, computers and other devices. 

Of the over 400 million people worldwide with various retinal diseases, nearly half of them (approximately 170 million) suffer from some sort of AMD (source) (source). Of the total macular degeneration patient population, it is estimated that roughly 90% suffer from dry AMD, which has no cure or therapy (source).

The other 10% are referred to as Wet AMD, which is treated by several drugs that only slow the progression.

The Solution


AR technology proven to enhance

vision!


Eyedaptic has harnessed the power of augmented reality technology to create a pair of glasses that simulate natural vision. Eyedaptic’s EYE2 glasses are the only self-contained Augmented Reality (AR) glasses on the market that capture over 40 degrees of the patients’ FOV (field of view).

*All images are of past prototypes or our production product. Final results may differ.


We also will be launching two new products. The EYE3 will be our new premier model, featuring the highest FOV of any self-contained AR visual aid that we have seen. The EYE4 will serve as our value model and will be priced below our current EYE2 model. This model will be ultra-light, weighing in at just 80 grams that can be connected to your cell phone. 

*All images are of past prototypes or our production product. Final results may differ.


Our glasses have an adaptive user interface for hands-free autonomous usage, as well as a range of controls to customize the user experience. This allows users to function more normally with a more natural viewing experience.

The Market


A billion dollar market opportunity

The retinal disease therapeutics market was valued at $11.04 billion and is projected to reach $21.3 billion by the end of 2026, growing at a CAGR of 8.6% in the forecast period. The global assistive technologies for the visually impaired market is expected to reach $6.57 Billion by 2025. With life expectancy increasing all the time, this issue is bound to become more prevalent, placing increasing pressure on the ophthalmic industry. (source

A comparable industry is that of global hearing aids, which has a similar market size, demographics, and direct consumer payable. The hearing aid market is worth over $8B today and is projected to reach $14.45B by 2026 (source). With a similar business model, and price points, and vision valued 7 times as much as hearing, we believe this is a billion-dollar market opportunity. (source)

Source

Our Traction


Patented Technology and Strategic Partnership with the World Leader in Low Vision Aids

We have already been awarded two patents, three trademarks, and currently have 12 more patent applications pending. Our one-of-a-kind AR visual aid solution enables AMD patients to perform everyday tasks and remain independent. In a clinical study, our participants saw a 5x improvement in task completion when using our product. 

After a clinical study and a beta product release, Eyedaptic launched at the end of 2019 with its current iteration of hardware and software. In March, we announced our partnership with Vispero, the world-wide leader in low-vision aids and other assistive technologies. This provided us increased access to the low vision market.

In addition, we have a new pair of glasses that features enhanced image quality, form factor, and comfort. This product includes a new hardware platform, increased software capability and a redesigned user interface. The EYE3 is in user beta testing now with launch announcement coming soon & the EYE4 is in user benchmarking now with planned launch later in 2021. 


   

*These testimonials may not be representative of the experiences of other customers and are not a guarantee of future performance or success.

The Business Model


Distributed through MDs and ODs, with subscription model options & high profit margins

Eyedaptic glasses are distributed through low vision specialists, who are specialized optometrists, and also through our partner’s dealer network of low vision distributors. The glasses are sold on average at a price of $3K to $6K (priced in line with hearing aids). Our newer models, such as the EYE4 value model, will implement a monthly subscription option, which brings the upfront cost down to just $1500 with an additional $50 monthly fee for software.

The retailer will potentially make roughly 20% to 30% margin. Cost of Goods is in the $500 to $1500 range, leaving a Gross Margin in the range of 50% to 70%. We also plan to distribute through general optometrists, which will produce similar profit margins.

Our USA pilot partnership with Vispero is one in which they act as our distributor and support partner. This enables quicker servicing of the market and scalability, and lower expense overhead. This creates a lower need for working capital in sales, marketing, and logistics. This can also potentially provide access to additional markets around the world in the future.


Eyedaptic’s current channels for lead generation and sales include direct to consumer advertising and referrals from local doctors. We continue to test the model as we scale our engagement. However, once our product becomes more widely used and supported by MDs and ODs, we aim to develop a direct-to-consumer model, much like that of the hearing aid industry. 

What We Do


Simulating natural vision with ease and comfort!

At Eyedaptic, we make augmented reality (AR) glasses specialized for people with AMD. We first start with open market AR glasses that have satisfactory Field of View (FOV) 

How We Are Different


No other visual aid like ours exists on the market!

The basic concept for a product like ours was first conceived by NASA about 30 years ago. However, wearable electronic technology is relatively new. Until recently, a comfortable, mobile, wearable solution with the computing power to handle advanced image processing and machine learning algorithms simply did not exist.


Our proprietary software, which uses image enhancement, pixel remapping and machine learning, provides both enhanced vision as well as a natural viewing experience. 

*All images are of past prototypes or our production product. Final results may differ.

Our algorithms perform double duty, first analyzing images, then monitoring the embedded motion sensor data to infer the user’s focus of attention. In addition, the software enhances images to help the user see the real world more clearly and optimize their remaining peripheral vision.


Based on our surveys most visual aids on the market today are essentially magnification devices like magnifying glasses or CCTV systems. These only work for close up tasks, and are not hands free for mobility.

Our product is an FDA Class I Exempt device, which does not require FDA approval or clinical trials to go to market. Our visual aid allows for major cost savings and enables a more frequent product update cycle.


We believe based on feedback from our customers that competitors have tried to create similar concepts with Virtual Reality (VR), but the head mounted devices are heavy and cumbersome. Also, they isolate the user from the real world, handicapping the user by cutting off their peripheral vision entirely.

The Vision


We aim to be world leader in wearable visual aids

Eyedaptic’s ultimate mission is to be the leader in our space. We envision being the primary manufacturer of the market-leading wearable visual aid device that simulates natural vision. 

*All images are of past prototypes or our production product. Final results may differ.

OUR LEADERSHIP


A unique blend of expertise in technology, optometry, ophthalmology, engineering and business

CEO, Jay Cormier, and CTO, Dave Watola, are both experienced technology executives. They have had successful careers at both hardware and software companies with multiple successful exits under their belts. Their MD co-founders,  Dr. Mitul Mehta and Dr. Brian Kim, are both retina specialists who see many AMD patients on a daily basis. Both have software and engineering backgrounds to successfully bridge any gaps between the technology and the patient.

Our board of advisors are amongst world leaders in the fields of ophthalmology, optometry, and low vision specialization. All have long, successful track records in helping people with eye conditions. Our board of directors is composed of successful and experienced early-stage CEOs and investors.

Why Invest


Eyedaptic is backed by some of the leading Angel Investor Groups and has the ability to change millions of lives

In the last year, Eyedaptic has received multiple awards across a variety of ophthalmology and technology organizations. A few noteworthy accolades include:


  • 2020 Vision Tank Start-Up Competition winner

  • 2020 Orange County High Tech Award Finalist

  • 2020 SXSW Pitch Finalist, 

  • 2nd place at Quick Pitch San Diego, 

  • Nominee for Orange County Business Journal’s Top Innovators of the Year

*All images are of past prototypes or our production product. Final results may differ.

Eyedaptic is serving one of the largest unmet needs in medical vision today, with over 150 million people affected worldwide (source, source, source, source)  Our one-of-a-kind AR visual aid solution enables AMD patients to perform everyday tasks and remain independent.

With multiple successful exits under our belts, a proven market model, and an experienced team that understands both the technology and medical fields, we have the necessary components to potentially make Eyedaptic the world leader in wearable visual aids. We have already secured investments from Tech Coast Angels, Band of Angels, and New York Angels, and members of the America Retina Forum. With your help and this raise, we are just one step closer to improving lives all over the world. 

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY.  THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS.  INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

Quick Insert

ABOUT

HEADQUARTERS

23421 South Pointe Drive
Laguna Hills, CA 92653
VALUATION

$12.03M

Eyedaptic glasses use augmented reality technology to improve vision for those who suffer from AMD (age-related macular degeneration) and other central vision impairments.

TEAM

Jay Cormier
Jay Cormier
CEO & Founder

As an experienced technology executive and entrepreneur, Jay has a strong track record of founding, growing, and turning around businesses. He has completed several successful exits totaling over $750M, across embedded software, SaaS, and hardware solutions. By leveraging his background at Analog Devices, Jay has led marketing, sales, engineering, operations, strategic partnerships, business development, new product strategy and execution. As Vice President & General Manager, Jay achieved exits at Teridian, Sierra Monolithics and Mindspeed using his expertise building high performance, execution-oriented multi-disciplinary teams. Jay earned his BS in Electrical Engineering from Worcester Polytechnic Institute and an MBA from Northeastern University.

Dave Watola
Dave Watola
Chief Technology Officer & Cofounder

Dave began his career at the Caltech/NASA Jet Propulsion Laboratory after earning his BS and MS in Electrical Engineering at Washington State University. There he researched and implemented advanced receivers, statistical pattern recognition systems, machine learning algorithms and error correcting codes for their Communication Systems Research Section. He went on to help co-found Pivotal Technologies, developing IP for the then-emerging Bluetooth and DVI arena, and was later acquired by Broadcom. He continued his startup work at Solarflare Communications, where he was deeply involved in all aspects of the technology. Dave has subsequently been applying image processing, machine learning, and statistical pattern recognition and decision making techniques to numerous cross-disciplinary software solutions.

Mitul Mehta, MD, MS
Mitul Mehta, MD, MS
Chief Medical Officer & Cofounder

Mitul is a board-certified ophthalmologist with fellowship training in medical and surgical diseases of the retina and practices at UCI’s Gavin Herbert Eye Institute. He earned his Medical Degree from the Keck School of Medicine of USC, and also holds a M.S. in BioPhysics from Georgetown and B.S. from MIT, where he first ventured into software startups. He completed fellowship training in vitreoretinal surgery at the New York Eye & Ear, and conducts research on surgical devices and techniques, as well as on vitreoretinal diseases, such as diabetic retinopathy and macular degeneration. Mitul is the cofounder of the online America Retina Forum and the Young Retina Forum as well as the editor of the retina section for the surgical education website, CSurgeries.com.

Brian Kim, MD
Brian Kim, MD
Medical Advisor & Cofounder

Brian is a board certified ophthalmologist at Harvard Eye Associates who specializes in the clinical treatment of retinal and macular diseases including macular degeneration, diabetic retinopathy, retinal vascular occlusions and other retinal conditions. He received his B.S. in Mechanical Engineering from Columbia University, and after graduation worked as a database programmer for Accenture in the pharmaceutical and biotechnology division. Brian went on to earn his Medical Degree from Pennsylvania State University, and completed a fellowship in Medical Retina at the Bascom Palmer Eye Institute in Florida, and has more than 15 published and presented novel research projects.

Art Reidel

Art Reidel

Board Director

Art has helped build and scale profitable businesses in the pharmaceutical software, electronic design automation, and communications industries for more than 40 years. He was CEO of Scintera and co-founder, chairman and CEO of Pharsight Corporation, where he led its IPO. In addition to his management roles, Art is well known in the investment community, and was a venture partner at Lightspeed Venture Partners, a general partner of ABS, and currently a Managing Partner at Horizon Ventures. He has recently served as acting President of WhiteHat Security, Chairman of Eye-Fi and Entelos, and currently is a Director of Materna Medical. Art has been an active member of the Band of Angels since 1995, is a partner in the Band’s Acorn fund and earned a B.S. in Mathematics from MIT.

Jerry Fitch

Jerry Fitch

Board Director

Jerry is an active Advisory Board member of the EvoNexus Incubator, as well as Okami Medical and Inceptus Medical Device Incubator. As President & CEO, he led the spinout of Teridian Semiconductor Corp. in conjunction with private equity firm Golden Gate Capital. He successfully transitioned the turnaround of the company, into the clean tech space which was subsequently sold to Maxim Integrated Products for $315M in cash, a 14x multiple in total invested capital. Prior to joining Teridian, Jerry was the CFO of Airport Group Inc. whose primary investors included The Soros Quantum Fund, GE Capital, and Lockheed Martin. Jerry graduated from the University of Southern California with BS in Business.

TERMS

Eyedaptic
Overview
PRICE PER SHARE
$0.80
DEADLINE
Oct 15, 2021
VALUATION
$12.03M
AMOUNT RAISED
$665,255.45
Breakdown
MIN INVESTMENT
$249.60
MAX INVESTMENT
$107,000.00
MIN NUMBER OF SHARES OFFERED
12,500
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Non-Voting Common Stock
MAX NUMBER OF SHARES OFFERED
1,337,500

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Eyedaptic, Inc.

Corporate Address

:

23421 South Pointe Drive, Laguna Hills, CA 92653

Offering Minimum

:

$10,000.00

Offering Maximum

:

$1,070,000.00

Minimum Investment Amount

(per investor)

:

$249.60











Terms


Offering Type

:

Equity

Security Name

:

Non-Voting Common Stock

Minimum Number of Shares Offered

:

12,500

Maximum Number of Shares Offered

:

1,337,500

Price per Share

:

$0.80

Pre-Money Valuation

:

$12,029,635.20











 COVID Relief

This offering is being conducted on an expedited basis due to circumstances relating to COVID-19 and pursuant to the SEC’s temporary regulatory COVID-19 relief set out in Regulation Crowdfunding §227.201(z).

Expedited closing sooner than 21 days

In reliance on Regulation Crowdfunding §227.303(g)(2) A funding portal that is an intermediary in a transaction involving the offer or sale of securities initiated between May 4, 2020, and February 28, 2021, in reliance on section 4(a)(6) of the Securities Act (15 U.S.C. 77d(a)(6)) by an issuer that is conducting an offering on an expedited basis due to circumstances relating to COVID-19 shall not be required to comply with the requirement in paragraph (e)(3)(i) of this section that a funding portal shall not direct transmission of funds earlier than 21 days after the date on which the intermediary makes publicly available on its platform the information required to be provided by the issuer under §§227.201 and 227.203(a).

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Company Perks*

Time-Based:

Friends and Family Early Birds:

Invest within the first week and receive an additional 20% bonus shares

 Super Early Bird Bonus:

Invest within the first two weeks and receive an additional 15% bonus shares

Early Bird Bonus:

Invest within the first three weeks and receive an additional 10% bonus shares

 Last Chance Bonus:

Invest within the first four weeks and receive an additional 5% bonus shares

Amount-Based:

Amount-Based:

Tier 1:  $500+

Quarterly Investor Newsletter from the CEO

Tier 2:  $1,000+

5% Bonus Shares

Tier 3: $2,500+

5% Product Price Discount

Tier 4: $5,000+

5% Product Price Discount

5% Bonus Shares

Tier 5: $10,000+

10% Product Price Discount

 7% Bonus Shares

Tier 6: $25,000+

15% Product Price Discount

10% Bonus Shares

Tier 7: $50,000+

Early new product access for Beta product

15% Bonus Shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Eyedaptic, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of non-voting common stock at $0.80/share, you will receive and own 110 shares for $80. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

*Concurrently with this offering, the Company may seek to raise funds in other offerings exempt from registration.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”.

PRESS

Article Image
2020 Vision Tank Start-Up Competition Winners

Article Image
Village TV

Watch Eyedaptic’s co-founder Dr. Kim, give insights on Augmented Reality glasses to help those with AMD see a better future

Article Image
Future of Personal Health: A CEO Explains How His Company Is Using Augmented Reality Technology to Counteract Vision Loss

Article Image
SXSW Conference

Eyedaptic Selected As Finalist For 2020 SXSW Pitch

Article Image
San Diego Business Journal

2019 Quick Pitch Competition Achieves Sold-Out Success

ALL UPDATES

10.24.22

Eyedaptic Launches the all new EYE5!

Hello Eyedaptic Community,

We have launched our newest product the EYE5, which includes all new features driven by Artificial Intelligence in a brand new glasses platform.  Our early users love the product for its comfort, simplicity and powerful vision enhancing features.  You can read the press release here:

https://www.prweb.com/releases/2022/10/prweb18958772.htm

Feel free to visit our updated website for more information at:

https://eyedaptic.com/eye5/

Thanks for supporting the future of vision technology,

The Eyedaptic Team


07.19.22

Eyedaptic News & Progress

Hello Eyedaptic Investors,

We have more great news to share - we have just received our 6th Patent grant this week!  With 14 more pending we have a powerful and growing patent portfolio.  You can read more about the latest patent here:

Eyedaptic’s 6th Patent Granted

Also, our users are finding ever more use cases for our newest products.  Here is a picture of Chuck enjoying the casino again.  We will continue to keep you posted.

Thanks to all for supporting the future of enhanced vision,

The Eyedaptic Team


10.14.21

It's World Sight Day - Hurry Invest Now!

Hello Eyedaptic Followers,


It is world sight day, and we are on a mission to help those with low vision with our breakthrough technology.

Our campaign is closing NOW so hurry if you want to make an investment before it is too late!


Thank to all for supporting the future of sight,

The Eyedaptic Team



10.14.21

FINAL CALL - Campaign Closing - Hurry Invest Now!

Hello Eyedaptic Followers,


Our campaign is closing NOW so hurry if you want to make an investment before it is too late!

If you want to help millions of people with low vision, and invest in technology to enable the mission, this is your last and final chance to invest in Eyedaptic!! 


Thank to all for supporting the future of augmented reality and vision,

The Eyedaptic Team


10.13.21

Only 1 day before campaign close - Hurry Invest Now!

Hello Eyedaptic Followers,


Our campaign closes TOMORROW so hurry if you want to make an investment before the opportunity passes by.

Be part of bringing our technology to people across the USA and around the Globe! 


Thank you for supporting the future of enhanced vision,

The Eyedaptic Team


10.13.21

Product Feedback is Great - Hurry Invest Now!

Hello Eyedaptic Supporters,


We have been delighted with the feedback from our dealers and doctors on our new products the EYE3 & EYE4!  

We now have the only wearable smart glasses visual aids, that include both a fully self contained model as well as the lightest weight and most comfortable models on the market!!


Thanks for supporting the future of augmented vision technology,

The Eyedaptic Team


10.12.21

Only 2 days remaining - Hurry Invest Now!

Hello Eyedaptic Followers,


Our campaign closes in only two days and you will no longer have the opportunity to invest in the amazing things we’re doing.

Help us reach even more people, that have Macular Degeneration and low vision, lead a more independent life! 


Thank you for supporting the future of augmented vision,

The Eyedaptic Team


10.11.21

Our customers love Eyedaptic - Hurry Invest Now!

Hello Eyedaptic Supporters,


Our customers are ecstatic with both our new products the EYE3 & EYE4!  

We now successfully span the market for low vision aids, with the best wearable glasses technology.  Join us in helping more people with vision impairments, and invest before time runs out!!


Thanks for supporting the future of vision technology,

The Eyedaptic Team



10.11.21

Only 3 days remaining - Hurry Invest Now!

Hello Eyedaptic Followers,


Our campaign closes in a few days and you will no longer have the opportunity to invest in the amazing things we’re doing.

Join us as we serve one of the largest unmet needs in medical vision today and help the more than 400 people worldwide suffering from retinal diseases.


Thank you for supporting the future of vision,

The Eyedaptic Team

10.08.21

A great year! Only 6 days until campaign close - Hurry Invest Now!

Hello Eyedaptic Supporters,


Eyedaptic has had a great year with two new products, three new granted patents and record revenues!  Our technology is helping blind people see and live a more independent life!  


We have only a few days left before the campaign closes, so hurry and invest now!


Thank you for supporting the future of vision,

The Eyedaptic Team


REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Eyedaptic.

$250.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$500.00

Tier 1

Quarterly Investor Newsletter from the CEO.

$1,000.00

Tier 2

5% Bonus Shares

$2,500.00

Tier 3

5% Product Price Discount

$5,000.00

Tier 4

5% Product Price Discount + 5% Bonus Shares

$10,000.00

Tier 5

10% Product Price Discount + 7% Bonus Shares

$25,000.00

Tier 6

15% Product Price Discount + 10% Bonus Shares

$50,000.00

Tier 7

Early new product access for Beta product + 15% Bonus Shares

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$665,255.45
INVESTORS
648
MIN INVEST
$249.60
VALUATION
$12.03M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.